Kappa Light Chains

Cancer

Report in 120Hrs

At Home

No Fasting Required

Details

Measures immunoglobulin light chains.

₹4,721₹6,745

30% OFF

Kappa Light Chains - Comprehensive Medical Test Information Guide

Section 1: Why is it done?
- Test Overview: Kappa light chains are immunoglobulin proteins produced by plasma cells. This test measures the concentration of kappa light chains in serum (blood) or urine. Light chains are components of antibodies and when produced in excess, may indicate abnormal plasma cell proliferation.
- Primary Indications for Testing: Diagnosis and monitoring of multiple myeloma, Waldenström macroglobulinemia, light chain disease, amyloidosis, and other plasma cell dyscrasias
- Clinical Reasons for Ordering: Evaluation of monoclonal protein in serum, assessment of renal dysfunction with proteinuria, evaluation of immunodeficiency, suspected hematologic malignancy, and screening for light chain disease
- Typical Timing: Performed when monoclonal gammopathy is suspected or detected, at diagnosis of plasma cell disorders, during treatment monitoring, at follow-up visits for established plasma cell malignancies, and when acute kidney injury is unexplained
Section 2: Normal Range
- Serum Kappa Light Chain Reference Range: 0.33 - 1.94 mg/dL (or 33 - 194 mg/L), depending on the laboratory and assay methodology used
- Kappa/Lambda Ratio: 0.26 - 1.65 (normal ratio indicates balanced production of kappa and lambda light chains)
- Urine Kappa Light Chain: Less than 2.0 mg/24 hours (or negative/trace on routine urinalysis)
- Interpretation of Results: Normal - Kappa levels within reference range with balanced kappa/lambda ratio, indicating polyclonal (normal) immunoglobulin production. Elevated - Kappa levels above reference range or ratio >1.65 suggests monoclonal (abnormal) plasma cell production. Low - Kappa levels below reference range or ratio <0.26 may indicate kappa suppression with lambda excess.
- Units of Measurement: mg/dL (milligrams per deciliter) for serum, mg/24hr for 24-hour urine collection, or mg/L depending on laboratory
- Clinical Significance: Normal results do not exclude plasma cell disorders but make them less likely. Results must be interpreted in clinical context with other immunologic markers. Any significant deviation warrants further investigation.
Section 3: Interpretation
- Markedly Elevated Kappa Light Chains (>5 mg/dL): Strongly suggestive of monoclonal plasma cell disorder such as multiple myeloma, light chain disease, or Waldenström macroglobulinemia. Increased risk of kidney injury from light chain deposition.
- Mildly to Moderately Elevated Kappa (1.95-5 mg/dL): May indicate monoclonal gammopathy of undetermined significance (MGUS), light chain MGUS, or early-stage plasma cell malignancy. Requires clinical correlation and follow-up testing.
- Abnormal Kappa/Lambda Ratio with Normal Kappa Level: Indicates clonal restriction of light chain production even when absolute levels appear normal. May represent small monoclonal protein burden or early disease.
- Elevated Kappa in Urine: Indicates urinary excretion of kappa light chains (Bence Jones proteinuria). Significant predictor of kidney damage, particularly in light chain disease. Requires assessment of renal function and consideration of treatment.
- Low Kappa with High Lambda (Ratio <0.26): Indicates monoclonal lambda light chain excess. Associated with plasma cell malignancies preferentially producing lambda light chains. Requires similar investigation and follow-up as elevated kappa.
- Factors Affecting Results: Renal function (decreased clearance elevates levels), dehydration, infection or inflammation (causes polyclonal increase), immunosuppression, recent chemotherapy (may transiently lower levels), and laboratory methodology variations. Serial measurements are more informative than single values.
- Clinical Significance Patterns: Rising levels suggest disease progression; falling levels indicate treatment response. Persistent elevation despite treatment may indicate treatment resistance. Combined with serum/urine protein electrophoresis, immunofixation, and immunoglobulin levels, kappa light chains provide critical diagnostic and prognostic information.
Section 4: Associated Organs
- Primary Organ Systems: Bone marrow (site of plasma cell production), lymphatic system (involvement in lymphoproliferative disorders), kidneys (primary site of light chain filtration and potential damage), and blood/circulatory system (where light chains circulate).
- Associated Hematologic Malignancies: Multiple myeloma (most common), light chain disease/light chain myeloma, Waldenström macroglobulinemia, AL amyloidosis, primary amyloidosis with cardiac or renal involvement, and other plasma cell dyscrasias.
- Renal Complications: Light chain nephropathy ("myeloma kidney"), acute kidney injury from light chain precipitation, chronic kidney disease, light chain cast nephropathy, and progressive renal failure requiring dialysis or transplantation.
- Systemic Involvement: Amyloid deposition in organs (heart causing restrictive cardiomyopathy, nervous system causing neuropathy, GI tract causing motility disorders), hepatomegaly, splenomegaly, and pathologic fractures from bone involvement.
- Complications of Abnormal Results: Progressive kidney damage, electrolyte abnormalities, hypertension, anemia, bone disease (hypercalcemia, lytic lesions, osteoporosis), hyperviscosity syndrome, and potentially fatal organ failure if untreated. Elevated light chains indicate urgency of intervention.
- Prognosis Association: Significantly elevated kappa light chains (>50 mg/dL) or abnormal kappa/lambda ratio is poor prognostic indicator in multiple myeloma. Light chain-only disease carries higher risk of renal involvement and worse outcomes than intact immunoglobulin myeloma.
Section 5: Follow-up Tests
- Immediate Confirmatory Tests: Serum protein electrophoresis (SPEP) to identify monoclonal protein spike, immunofixation electrophoresis (IFE) for light chain type confirmation, lambda light chain level for kappa/lambda ratio calculation, and 24-hour urine protein and immunofixation for Bence Jones protein detection.
- Comprehensive Immunologic Evaluation: Serum immunoglobulins (IgG, IgA, IgM) to assess complete immunoglobulin profile, free light chain analysis (alternative measurement method), complete blood count (CBC) for anemia and leukopenia assessment, and flow cytometry for plasma cell characterization.
- Renal Function Assessment: Serum creatinine and calculated glomerular filtration rate (eGFR) to assess kidney function, serum electrolytes (sodium, potassium, calcium, phosphate), urinalysis to evaluate proteinuria and hematuria, and 24-hour creatinine clearance for more accurate GFR estimation.
- Bone Marrow and Imaging Studies: Bone marrow aspirate and biopsy for plasma cell percentage and morphology, skeletal survey or PET-CT for lytic bone lesions, MRI of spine for occult bone disease, and staging studies (CT, PET) for suspected malignancy.
- Prognostic and Specialized Tests: Fluorescence in situ hybridization (FISH) for cytogenetic abnormalities, beta-2 microglobulin level, lactate dehydrogenase (LDH), albumin level, and cytogenetic analysis for prognostic stratification.
- Monitoring Frequency: At diagnosis: baseline testing, During active treatment: every 2-4 weeks, Post-treatment: every 3 months for 2 years, Maintenance phase: every 4-6 weeks, After remission: every 2-3 months for first year then less frequently. More frequent monitoring with markedly elevated levels (>50 mg/dL).
- Specialized Follow-up for Complications: Echocardiogram if cardiac amyloidosis suspected, nerve conduction studies for peripheral neuropathy assessment, tissue biopsy (kidney, cardiac, GI) for amyloid confirmation with Congo red staining and mass spectrometry, and ophthalmology evaluation for ocular manifestations.
Section 6: Fasting Required?
- Fasting Requirement: NO - Fasting is NOT required for kappa light chain testing. This is a non-fasting test and can be performed at any time of day.
- Specimen Collection: Serum specimen - standard venipuncture into gold-top or silica gel tube (serum separator tube). Urine specimen - 24-hour urine collection in sterile container, or first morning void for random urinalysis. No special processing required.
- Medication Considerations: No medications need to be withheld before testing. Current medications do not significantly affect results. Continue all routine medications as prescribed. Inform laboratory of any recent chemotherapy or immunosuppressive therapy.
- Patient Preparation Instructions: Serum test - Patient may eat and drink normally before visit, Maintain adequate hydration, Wear comfortable clothing for easy venipuncture. Urine test - For 24-hour collection, discard first morning void, then collect all urine for next 24 hours in provided container, Store collection in cool place or refrigerate if collection extends multiple hours.
- Special Instructions: Avoid strenuous exercise 24 hours before testing if possible, Maintain normal fluid intake to avoid dehydration or overhydration, For 24-hour urine: ensure complete collection for accurate results, notify lab if collection was compromised. Specimen stability: serum samples stable 1 week at room temperature or 4-6 weeks refrigerated.

How our test process works!